Please provide your email address to receive an email when new articles are posted on . A home-based cardiac rehabilitation program improved functional capacity and was associated with regaining ...

Use of a mobile app was not associated with better cardiac outcomes or completing a cardiac rehabilitation program. Prior studies have shown the potential of mobile apps in transforming cardiac rehab, ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy.The agency approved 5 mg, 10 mg, 15 ...

AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 treatment resulted in a statistically significant ...

Compared with placebo, a significant improvement in cardiac functional capacity was observed among caficrestat-treated patients not receiving concomitant SGLT2is or GLP-1 RAs. Treatment with ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular ...